Hyasynth Bio

About:

We make Better Cannabinoids through sustainable biotechnology.

Top Investors: SOSV, OrganiGram, MassChallenge, Anges Quebec, Hedgewood

Description:

We’re a bioengineering company that's reducing the massive environmental footprint of the CBD market through precision fermentation. And our technology never touches a plant. CBD is a global $12Bn consumer market and Hyasynth's precision fermentation platform eliminates wasteful plant cultivation and decreases the carbon impact by more than 97%. Hyasynth is the world's only bioengineering company with a scalable, fermentation process for CBD that is cost-efficient and regulatory-compliant.

Total Funding Amount:

$13.2M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Montréal, Quebec, Canada

Founded Date:

2014-05-01

Contact Email:

info(AT)hyasynthbio.com

Founders:

Alex Campbell, Kevin Chen, Shoham Mookerjee, Si Ch, Zach Wiltshire

Number of Employees:

11-50

Last Funding Date:

2021-12-22

IPO Status:

Private

Industries: